Article No
W072-3
Anti-CD358 (DR6) (Human) mAb
Anti-CD358 (DR6) (Human) mAb
Antibodies Primary
Specifications
| Application | FC |
| Article No | W072-3 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT, FO, GL |
| Clone | 3E2E4 |
| Clone Type | monoclonal |
| Description | Anti-CD358 (DR6) (Human) mAb |
| Supplier | MBL |
| Immunogen | Human CD358 (DR6) expressed Ba/F3 transfectants generated from SST-REX (signal sequence trap by retrovirus-mediated expression screening). |
| Isotype | IgG2a k |
| Notes | Death receptor 6 (DR6), also known as CD358 or TNFRSF21, is a member of the tumor necrosis factor receptor superfamily. DR6 contains a death domain and four TNFR-Cys repeats. It is highly expressed in the heart, brain, placenta, pancreas, lymph nodes, thymus, and prostate. DR6 activates nuclear factor kappa-B and mitogen-activated protein kinase 8 and induces cell apoptosis. Overexpression of DR6 has been observed in several cancers including ovarian cancer and sarcoma. |
| Product Type | Antibodies Primary |
| Shipping Information | 4°C |
| Size | 100 µl |
| Source / Host | mouse |
| Species Reactivity | human |
| Storage | -20°C |
| Substrate / Buffer | 1 mg/mL in PBS/50% glycerol, pH 7.2 |
| Technical Specifications | Death receptor 6 (DR6), also known as CD358 or TNFRSF21, is a member of the tumor necrosis factor receptor superfamily. DR6 contains a death domain and four TNFR-Cys repeats. It is highly expressed in the heart, brain, placenta, pancreas, lymph nodes, thymus, and prostate. DR6 activates nuclear factor kappa-B and mitogen-activated protein kinase 8 and induces cell apoptosis. Overexpression of DR6 has been observed in several cancers including ovarian cancer and sarcoma. |
| Product Page Updated | 2023-12-29T16:20:16.638Z |
